Impact of nirsevimab immunization on admissions at a tertiary hospital
Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026-04 · 44 (4) · 503138
DOI: 10.1016/j.eimce.2026.503138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2026-04. Verfasst von Manuel Oltra-Benavent und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Pediatría, Hospital Universitari i Politècnic La Fe, Valencia, Spain. Electronic address: oltra.benavent@gmail.com. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Patient Admission. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION The efficacy of nirsevimab for the prevention of respiratory syncytial virus (RSV) infection has shown good real-life results. The objective was to investigate the impact of a nirsevimab immunisation strategy on admissions due to RSV and bronchiolitis caused by other viruses in a tertiary care hospital. PATIENTS AND METHODS Cohort study comparing the cumulative incidence of admissions due to RSV and other respiratory viruses in a tertiary care hospital in two consecutive epidemic seasons. The population of the second season underwent a population-based intervention consisting of the administration of nirsevimab to newborns and children under 6 months of age (intervention group), which did not occur in the first season (control group). Frequency and association measures were calculated. RESULTS Immunization coverage was 93.8% in maternity wards and 89.2% in primary care. During the intervention season, 40 infants under 6 months of age were admitted compared to 147 during the control season, with a percentage of admissions to the Intensive Care Unit (ICU) of 0.05% and 0.6%, respectively. The RRR was 70.7% (IC 95: 57,2 a 80) in infants aged 1-6 months, 80.6% (IC 95: 53,7 a 91,9) in newborns, and 90.9% (IC 95: 29,8 a 98,8) in the ICU. No newborns from January to March of either season were admitted with RSV infection. The RR for rhinovirus and metapneumovirus bronchiolitis during the intervention season was 1.52 (IC 95: 1,17 a 1,98) and 1.66 (IC 95: 1,35 a 2,04), respectively. CONCLUSION The reduction in RSV admissions in a tertiary hospital, after immunisation with nirsevimab in real-life settings is significant, and is more significant in neonatal units and ICUs. Immunisation in maternity wards from January to March had no impact. The increased RR of hospitalisation due to rhinovirus and metapneumovirus bronchiolitis requires further studies to infer causality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Servicio de Pediatría, Hospital Universitari i Politècnic La Fe, Valencia, Spain. Electronic address: oltra.benavent@gmail.com.
- Servicio de Pediatría, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- Servicio de Microbiología, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- Salut Pública, Consejería de Sanidad, Valencia, Spain.
Zitieren
APA
Oltra-Benavent, M., Suay-Romero, R., Muro-Díaz, E., Taberner-Pérez, P. J., Ferrer-Lorente, M. B., Ferrer-González, J. P., & Garcés-Sánchez, M. (2026). Impact of nirsevimab immunization on admissions at a tertiary hospital. Enfermedades infecciosas y microbiologia clinica (English ed.), 44(4), 503138. https://doi.org/10.1016/j.eimce.2026.503138
Vancouver
Oltra-Benavent M, Suay-Romero R, Muro-Díaz E, Taberner-Pérez PJ, Ferrer-Lorente MB, Ferrer-González JP, et al. Impact of nirsevimab immunization on admissions at a tertiary hospital. Enfermedades infecciosas y microbiologia clinica (English ed.). 2026;44(4):503138. doi:10.1016/j.eimce.2026.503138
BibTeX
@article{OltraBenavent2026,
author = {Oltra-Benavent, Manuel and Suay-Romero, Raquel and Muro-Díaz, Eva and Taberner-Pérez, Pablo Javier and Ferrer-Lorente, María Belén and Ferrer-González, Juan Pablo and Garcés-Sánchez, María},
title = {Impact of nirsevimab immunization on admissions at a tertiary hospital},
journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
year = {2026},
volume = {44},
number = {4},
pages = {503138},
doi = {10.1016/j.eimce.2026.503138}
}
EUVIMED